GBS(US:INBS) Globenewswireยท2025-01-29 14:00Core Insights - Intelligent Bio Solutions Inc. (INBS) has transitioned Quantum Traffic Management (Quantum TM) from traditional saliva and urine testing to a non-invasive, in-house fingerprint sweat-based drug screening solution [1][2] - Quantum TM, with over 30 years of experience, operates in various sectors and has adopted INBS' technology to enhance workplace testing efficiency and safety [2][5] - INBS plans to enter the US market in 2025, leveraging its FDA 510(k) submission and the growing global point-of-care (POC) drug screening market [4] Company Overview - Intelligent Bio Solutions Inc. specializes in innovative, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [6] - The system screens for commonly used drugs in the workplace, providing results in under ten minutes, making it suitable for safety-critical industries [6] - INBS currently serves over 400 accounts across 19 countries, including sectors like construction, manufacturing, transport, and logistics [4] Industry Context - Quantum TM has shifted to INBS' technology due to inefficiencies and delays associated with traditional testing methods, allowing for on-the-spot drug screening [2][3] - The adoption of fingerprint sweat-based testing represents a significant advancement in drug screening technology, offering a hygienic and cost-effective alternative [6] - The global POC drug screening market is rapidly expanding, presenting growth opportunities for companies like INBS [4]